Exhibit 10.5

Andy Hill Cancer Research Endowment Grant Award Agreement

This agreement (“Agreement”) is entered into by the Andy Hill Cancer Research Endowment (CARE) Fund, (“Grantor”), a grantmaking entity of the state of Washington, and Aptevo Therapeutics Inc. (“Grantee”), having an administrative office at 2401 4th Avenue Suite 1050, Seattle, WA 98121 and the US Federal Tax Identification Number [***]. The Grantor has delegated certain responsibilities to Grantor’s Program Administrator (“Administrator”) as described in this Agreement;

Grantor is authorized by statute of the state of Washington to make grants for the fundamental government purpose of promoting cancer research utilizing the best science and technology with the greatest potential to improve health outcomes, leveraging the state’s existing cancer research facilities and talent, creating jobs, and encouraging investments that will advance the biotech, medical device, and health care information technology industries in Washington State;

Grantor intends to sponsor cancer research and development under the direction of Michelle Nelson, (“Principal Investigator”), and provide funds as reimbursement on actual expenditures not to exceed One Million Four Hundred Ninety-Nine Thousand Nine Hundred Fifty-One Dollars and Zero Cents ($1,499,951.00) (the “Grant”) to Grantee to conduct such research and development;

Grantee intends to conduct the sponsored research and development in accordance with the grant proposal submitted to Grantor;

Administrator will provide administrative services and support to Grantor through the grant award and post-award processes, including but not limited to:

NOW, THEREFORE, in consideration of the above and the mutual terms and conditions set forth below, Grantor and Grantee agree as follows:

ARTICLE 1. EFFECTIVE DATE, GRANT PERIOD, ANNUAL PERIOD, AND ADMINISTRATION

This Agreement shall be effective upon execution by all parties or June 22, 2026, whichever is later, (“Effective Date”). The activities set forth in the Proposal and Milestones and Timeline (as defined in Sections 2.1 and 2.2) shall be performed during the period beginning on the Effective Date and ending no later than June 21, 2028 (“Grant Period”).

Notwithstanding that an annual period may be less than twelve months if this Agreement is executed after June 22, 2026, each “Annual Period” shall end June 21 of the applicable year. The first Annual Period shall be from the Effective Date to June 21, 2027. The second Annual Period shall be from June 22, 2027, to June 21, 2028.

For purposes of this Agreement, any and all rights or obligations of Grantor as stated herein may be exercised, undertaken, or performed on its behalf by Administrator, if and to the extent determined by Grantor from time to time and communicated in writing to Grantee. When and to the extent so

communicated, Grantee shall be entitled to rely on the representations, statements, and determinations made and/or conveyed by Administrator on Grantor’s behalf.

ARTICLE 2. DESCRIPTION OF RESEARCH AND DEVELOPMENT PROJECT

In the event that during the Grant Period the Principal Investigator(s) changes his or her employment status with Grantee, relocates outside of Washington, or otherwise is unable to fulfill the role of Principal Investigator(s), or an individual with the Key Personnel is no longer able to perform his or her responsibilities as described in the Proposal, Grantee shall notify Grantor [***] to such event, or [***], and identify in writing an alternate Principal Investigator(s) or Key Personnel member, acceptable to Grantor. At Grantor’s discretion, Grantee may be required to provide additional documentation prior to approval. Failure by Grantee to have either an approved Principal Investigator(s) or an approved full complement of Key Personnel are grounds for termination of this Agreement.

In the event that during the Grant Period the Principal Investigator(s) or other individuals performing the activities set forth in the Proposal and the Milestones and Timeline: (a) are debarred, declared ineligible, or voluntarily excluded from participation in transactions by any federal department or agency, including, but not limited to the U.S. Food and Drug Administration (“FDA”), or under any federal statute or regulation, including, but not limited to the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C.; or (b) are otherwise subject to restrictions or sanctions by any other governmental agency or professional body with respect to the performance of scientific or clinical investigations; or (c) have otherwise been disqualified or suspended from performing activities substantially the same as those set forth in the Proposal and the Milestones and Timeline; Grantee shall [***] notify Grantor in writing. Debarment, ineligibility, exclusion, or other disqualification or suspension of the Principal Investigator(s) or other individuals set to perform the activities set forth in the Proposal and the Milestones and Timeline from actually performing such activities are grounds for termination of this Agreement.

Subject to the terms of this Agreement, Grantee may engage third party Subcontractors, Collaborators, and Service Providers in performing the activities set forth in the Proposal or the Milestones and Timeline. Grantee shall be responsible for the performance of all such Subcontractors, Collaborators, and Service Providers and for ensuring that their work is consistent with the terms and conditions of this Agreement. Grantee certifies that it shall enter into written agreement(s) with all such Subcontractors, Collaborators, and Service Providers as specified in the Proposal and the Milestones and Timeline.

Among other provisions, such agreement(s) shall allow for the allocation of the rights that Grantee and Subcontractors, Collaborators, and Service Providers shall have in any intellectual property developed in

performing the activities set forth in the Proposal or the Milestones and Timeline and shall identify which of the parties shall be responsible for commercialization of such intellectual property. No privity of contract exists between Grantor and Subcontractors, Collaborators, and Service Providers.

For equipment (including replacement equipment) acquired in whole or in part with Grantor funds, Grantee must have procedures and control systems in place to:

When original or replacement equipment acquired with Grantor funds is no longer needed for the original project or program or for other activities currently or previously assisted with Grantor funds, the following rules of disposition will apply to Grantee:

ARTICLE 3. FUNDING AND PAYMENT

Grant payments are contingent on Grantee’s ability to demonstrate use of a minimum one-to-one (1:1) matching non-state or private contributions. For purposes of award of state funds, proof of non-state or private matching contributions may be demonstrated by:

State Matching Contributions (Attachment D)); or

Grantee shall promptly notify Grantor in writing of any change or expected change of the non-state match amount, source, or any other material change that may affect the Grantee’s ability to meet the non-state match commitment in Attachment D or complete the activities set forth in the Proposal and according to the Milestones and Timeline.

The terms and conditions of the Agreement and the CARE Fund statute, Chapter 43.348 Revised Code of Washington (RCW), shall be the final guides in determining allowable matching contributions.

Determinations of allowable matching contributions shall be made at [***] of the CARE Board.

The obligation of Grantor to disburse funds to Grantee under this Article 3 is contingent upon Grantor having sufficient funds, expenditure authorization, and authority under state or federal laws, regulations, or guidelines to do so, as determined by Grantor.

The following direct costs are generally allowable: personnel, including wages, benefits, stipends; computers and equipment (with Grantor pre-approval, and where the unit cost of what constitutes an item of equipment is subject to Grantee’s policies); supplies; travel; subcontracts; and other costs as itemized by Grantee and approved by Grantor. Facilities and administration costs are allowable at the Grantee’s federally negotiated indirect cost rate, or as otherwise approved by Grantor. Facilities and administration costs are allowable at the pro rata basis attributable to performing the activities set forth in the Proposal and the Milestones and Timeline.

Expenditures for the following are not allowable: costs not within the Budget, facilities construction and remodeling costs, acquisition of real property, meals not associated with approved travel or exceeding the state per diem guidelines, alcoholic beverages, costs associated with community service, teaching, clinical or patient care beyond those required for performing the activities set forth in the Proposal and the Milestones and Timeline, costs of purchasing, leasing, or maintaining computers not essential for performing the activities set forth in the Proposal and the Milestones and Timeline.

Grantee shall make commercially reasonable efforts to purchase goods and services from Washington State suppliers to the extent reasonably possible, where such goods and services are available, are comparable in quality and utility of the non-Washington State supplier, and comply with any relevant Washington State procurement policies.

The terms and conditions of the Agreement and the CARE Fund statute, Chapter 43.348 Revised Code of Washington (RCW), shall be the final guides in determining allowability. Determinations of allowable cost shall be made at the sole discretion of the CARE Board.

Additionally, significant rebudgeting, whether or not the particular expenditure(s) require prior approval, requires advance written approval from Grantor. Significant rebudgeting occurs when expenditures in a single direct cost budget category deviate (increase or decrease) from the categorical commitment level established for the annual budget period by more than 25 percent of the total project funding (from all sources) for the annual period as provided in Attachment C: Budget. For example, if the total project budget for a single budget period is $200,000, any rebudgeting that would result in an increase or decrease of more than $50,000 in a budget category is considered significant rebudgeting.

The base used for determining significant rebudgeting excludes the effects of prior-year carryover balances.

Grantees must demonstrate use of non-state match contributions as committed in Attachment D, or other acceptable non-state matching contribution approved by Grantor, and at least a 1:1 use of non-state match contributions to the previously disbursed grant award payments before invoicing any balance of the Grant.

Use of non-state match contributions may be demonstrated by submitting a financial summary report by budget category, certified by an authorized official that the expended funds were used to support the

activities of the Principal Investigator(s) as outlined in the Proposal, or closely related work that supports, extends, or facilitates the Proposal, and were from non-state sources.

At the Grantor’s discretion, more detailed information regarding Grant expenditures may be requested, including but not limited to invoices, receipts, canceled checks, or bank statements.

Commencing on the Effective Date, for each Annual Period, invoices shall be submitted after each Annual Period by electronic transmission as specified in Article 19. Invoices, annual progress reports, and annual financial reports shall be submitted [***] from the end of the Annual Period, or as otherwise agreed by Grantor and Grantee. Grantor, at its sole discretion, may deny payment of invoices submitted [***] after the Annual Period, or as otherwise agreed by Grantor and Grantee. Invoices shall be submitted by Grantee using Grantor’s standard invoice form, or Grantee’s standard invoice form if approved by Grantor in advance, and shall be accompanied by a document outlining milestone(s) met during the Annual Period; shall provide detailed expenditure documentation according to the categories within the Budget; shall demonstrate the use of non-state match contributions, at a minimum rate of 1:1 the invoiced amounts; and shall be signed by Grantee’s Authorized Official or designee certifying that all expenditures are directly related to the performance of the activities set forth in the Proposal, the Milestones and Timeline, and the Budget. Grantor, at its sole discretion, may accept invoices and supporting documentation and make grant payments more frequently than annually. Grantor reserves the right to withhold payment for invoices, which in Grantor’s sole discretion, are insufficiently documented.

Grantor shall provide payments to Grantee for all allowable costs until completion of the activities set forth in the Proposal and the Milestones and Timeline, expiration of the Grant Period, or notice of termination of this Agreement, whichever is earliest, insofar as such allowable costs do not exceed the Grant. Unexpended funds may not be carried into the next Annual Period unless approved by Grantor (Section 3.9). If for any reason, Grantee fails to demonstrate the use of non-state match contributions greater than or equal to the Grant, Grantee must repay the portion of the grant payments in excess of the demonstrated non-state match contribution use.

All payments under this Agreement shall be sent to Grantee via electronic funds transfer. CARE Fund grant payments will only be made to U.S.-domiciled banks. No payments of grant funds shall be made to financial institutions or offices thereof, that are outside the United States. Grantee shall not

request deposit or electronic transfer of payment from Grantor to any foreign banking office, including but not limited to (a) any non-U.S. office of a financial institution or (b) any non-U.S. office of a foreign bank as described in 12 U.S.C. 3101(7). Grantee shall complete and send a Grantee Banking Information Form and signed IRS Form W-9 to Grantor before any payments will be made. Grantee shall provide Grantor an updated Grantee Banking Information Form and W-9 as necessary to ensure that information is current and accurate.

Full payment of the Grant prior to the end of the Grant Period shall not be considered fulfillment of the terms of this Agreement or end of the Grant Period. All remaining terms and obligations under this Agreement shall remain in full force and effect until the end of the Grant Period or any applicable survival period specified in the Agreement.

In the event any amount of the Grant is refunded to Grantor, Grantee shall notify Grantor in writing of the amount to be refunded, expected date of the refund payment, and reason for the refund.

Requests for a Budget Supplement shall be submitted in writing by Grantee’s Authorized Official or Principal Investigator(s), or their designee, within [***] of the occurrence of the precipitating event. Provision of a Budget Supplement is subject to [***] of Grantor and the availability of funds. Grantor reserves the right to refer Budget Supplement requests for outside expert review, the cost of which shall be deducted from the Budget Supplement.

ARTICLE 4. PROGRESS REPORTS

All progress reports shall be of sufficient detail to allow Grantor to assess progress made on completing the activities set forth in the Proposal and the Milestones and Timeline, and how such activities contribute to Grantor’s mission. The annual progress reports should illustrate the leveraging effect achieved by the Grant, to include, but not limited to, [***]. In the event that Grantor determines that a progress report lacks sufficient detail, Grantee shall provide Grantor with additional detail in a timely manner as may be requested by Grantor. Grantee shall also disclose in writing to Grantor any problems, delays or adverse conditions which may materially affect its ability to complete the activities set forth in the Proposal and the Milestones and Timeline. Such disclosure shall be accompanied by a statement of the action taken or proposed and any assistance needed from Grantor to resolve the situation.

Information in the progress reports is received by the Grantor with the understanding that it shall be used or disclosed for the primary purpose of monitoring the Grantee’s progress related to the Proposal and the Milestones and Timeline or as required by law. Administrator or Grantor may also use information in Grantee’s progress reports to communicate to the public the impact of Grantor grant awards. Administrator and Grantor shall hold all progress reports confidential, subject to the public disclosure laws of the state of Washington (including but not limited to RCW 42.56 and associated case law). If a records request is made to the Administrator or Grantor, the Grantee may be notified and allowed an opportunity to seek a protective order. The CARE Fund will determine, in its [***], whether to assert RCW 42.56.270(29) or any other available public records exemption. Due to public disclosure requirements, it is advisable that Grantees refrain from sharing any information with the Grantor and Administrator, to the extent that such information, if revealed, would reasonably be expected to result in private loss to the providers of this information.

Upon the reasonable prior written request of Grantor and prior to expiration of the Grant Period, Grantee shall provide additional oral or written progress reports or arrange site visits or in-person briefings at a mutually agreed upon time and place to enable Grantor to assess the impact of the grant award.

written progress report and through [***] of submission of such final report, Grantee shall be asked to provide Grantor with periodic post-Grant Period written progress reports similar in scope to those produced during the Grant Period, to include but not limited to, [***]. This term shall survive termination of the Agreement.

Every [***], for up to [***], after submission of the final written progress report, Grantee shall be requested to submit a written report accounting for the capitalized equipment purchased in whole or in part with the Grant and the use and impact of the shared resource developed with the Grant.

ARTICLE 5. ACCOUNTING AND AUDITING

ARTICLE 6. INTELLECTUAL PROPERTY

Due to public disclosure requirements, it is advisable that Grantees refrain from sharing any information with the Grantor and Administrator, to the extent that such information, if revealed, would reasonably be expected to result in private loss to the providers of this information.

Invention reports shall commence with Grantee’s first Annual Progress Report, and subsequent reports shall be provided upon Grantor’s request. Invention reports shall be provided until a date [***] after the final Annual Progress Report. This term shall survive termination of the Agreement.

If Grantee decides not to take title and file an application for intellectual property protection, Grantor shall have the option to take title. The Grantee must notify Grantor prior to any publication of the invention so as to allow Grantor sufficient opportunity to take title and pursue or maintain intellectual property protection.

Grantor claims no ownership rights in any technology or intellectual property conceived, reduced to practice, or otherwise made in the course of performing the activities set forth in the Milestones and Timeline. Grantee agrees to use [***] to commercialize such technology or intellectual property.

obligations imposed upon Grantee in this Article 6.

ARTICLE 7. CONFLICT OF INTEREST

Grantee certifies that it has a conflict of interest policy, including but not necessarily limited to any financial conflict of interest policy, as required by the U.S. Department of Health and Human Services (DHHS)/Public Health Services (PHS), in place applicable to performing the activities set forth in the Proposal and the Milestones and Timeline, and that it has taken [***] to inform the Principal Investigator(s) and all personnel performing such activities of the policy and requirements for complying with its terms. In accepting the Grant, Grantee certifies that it has advised the Principal Investigator(s) and Grantee’s personnel performing the activities set forth in the Proposal and the Milestones and Timeline that they are required to disclose, in accordance with the foregoing policy, any potential financial conflicts of interest associated with their participation in such activities to Grantee and that it has received such disclosures or received an affirmative statement that there are no conflicts to disclose. Grantee further certifies that it has eliminated or mitigated all disclosed financial conflicts consistent with the terms of its policy. Grantee shall take [***] to ensure that its Subcontractors performing activities set forth in the Proposal and the Milestones and Timeline are aware of and have agreed to comply with the provisions in this Article 7.

At execution of this Agreement, Grantee shall provide to Grantor the completed and executed Conflict of Interest Report Form found in Attachment E regarding any potential financial conflicts of interest associated with personnel performing the activities set forth in the Proposal and the Milestones and Timeline, and further attesting to (1) Grantee’s receipt of disclosures from such personnel that, at a minimum, confirm understandings of Grantor as stated in Attachment E, and (2) elimination or mitigation of all disclosed potential conflicts of interest.

In the event that new financial conflicts of interest are disclosed during the course of performing activities set forth in the Proposal and the Milestones and Timeline, Grantee shall report such disclosures in writing to Grantor in a timely manner using the procedure specified within this Article 7.

Upon the request of Grantor, Grantee shall provide, in writing, information about any financial conflicts of interest that have been disclosed subject to this Article 7, or that have been identified by Grantor in Attachment E, and about how such disclosed or identified conflicts have been eliminated or mitigated.

ARTICLE 8. PRESENTATIONS, PUBLICATIONS, AND PUBLICITY BY GRANTEE

The parties recognize that the results from performance of the activities set forth in the Proposal and the Milestones and Timeline may be publishable and agree that the persons performing such activities shall be permitted, and are expected, to present the methods and results at symposia and professional meetings and to publish in journals, theses or dissertations, or otherwise, in a manner of their own choosing. Following any such publication, copies shall be submitted by Grantee to Grantor upon request.

Furthermore, the Grantee shall ensure that the Grantor-funded research and development is properly acknowledged in any presentation, journal article, public statements, press release, research report, or other material produced by, or on behalf of, the Grantee that relates to the activities set forth in the Proposal and the Milestones and Timeline. Acknowledgement of support shall use Grantor’s name and logos consistent with its guidelines and include the following information:

In any such acknowledgement, the relationship between the Grantor and Grantee shall be accurately and appropriately described.

The Grantor requests an opportunity to review publicity materials [***] prior to publication. Publicity of Grantor investment and Grantor supported impact is highly encouraged.

ARTICLE 9. REPRESENTATIONS OF GRANTEE AUTHORITY AND STATUS

In accepting the Grant, Grantee makes the following representations and certifies:

in criminal, civil, or administrative penalties; and

ARTICLE 10. USE OF HUMAN SUBJECTS AND VERTEBRATE ANIMALS

ARTICLE 11. TERMINATION

Timeline in a timely manner; or

No Grantor funds shall be obligated for any expenses incurred by Grantee on or after the Notice Date if Termination Event(s) is not cured within [***] cure period or such extended time to cure as may be agreed by the parties. In the event Grantee timely cures the Termination Event(s), allowable costs incurred after the Notice Date may be paid with Grantor funds.

In the event that the Grantee fails to perform this Agreement in accordance with state laws, federal

laws, and/or the provisions of this Agreement, Grantor reserves the right to recapture in whole or in part, Grant funds disbursed under the Agreement, in addition to any other remedies available at law or in equity.

Nothing herein shall be construed to release Grantor from any obligation to provide Grantor funds to Grantee for allowable costs incurred prior to the Notice Date. Upon termination, Grantee will be reimbursed [***] incurred prior to the Notice Date, not to exceed total Grant Period costs specified in Attachment C Budget. Unexpended and unobligated Grantor funds shall be returned to the Grantor within [***] of termination of this Agreement.

Expenditure authority for any unexpended funds shall revert to Grantor. Nothing herein shall be construed to release Grantee from any obligation which matured prior to the effective date of such termination or to waive any rights Grantor may have to recover damages incurred by it as a result of Grantee’s breach of the Agreement.

the foregoing, the following provisions of this Agreement shall survive any expiration or termination: Article 3, Funding and Payment; Article 4, Progress Reports; Article 5, Accounting and Auditing; Article 6, Intellectual Property; Article 8, Presentations, Publications, and Publicity by Grantee; Article 11, Termination; Article 12, Communications and Public Disclosures by Grantor; Article 13, Responsibility for Loss/Indemnification; Article 14, Failure to Enforce; Article 15, Relationship of the Parties; Article 16, Governing Law; Article 17, Assignment; Article 18, No Oral Modifications; Article 19, Notices; Article 20, Entire Agreement; Article 21, Force Majeure; Article 22, Severability; Article 23, Disputes; Article 24, No Third-Party Beneficiaries; and Article 25, Counterparts.

ARTICLE 12. COMMUNICATIONS AND PUBLIC DISCLOSURES BY GRANTOR

Grantor reserves the right to publicly disseminate information about this grant and Grantee’s activities as set forth in the Proposal and the Milestones and Timeline in public reports, on its website, in press releases, speaking engagements, and other public venues. Grantor shall not publicly disclose information that has been marked as proprietary or confidential, as is consistent in Grantor’s sole discretion, with RCW 42.56.270(29) or other applicable exemptions to public disclosure, if such information has not been previously disclosed to the public. From time-to-time Grantor may request Grantee or Principal Investigator(s) to assist Grantor with such communications and public disclosures pertaining to the activities set forth in the Proposal and the Milestones and Timeline. Such assistance provided by Grantee or Principal Investigator(s) shall be at reasonable times and locales and at Grantor’s expense.

ARTICLE 13. RESPONSIBILITY FOR LOSS/INDEMNIFICATION

To the fullest extent permitted by law, Grantee shall indemnify, defend, and hold harmless Grantor and Grantor’s officers, directors, agents, employees, and representatives (including without limitation, Administrator) from and against all claims, injuries, loss, liability and expense (including reasonable attorneys’ fees) resulting from the performance of the activities contemplated by, arising from, or taken in connection with the performance of the Proposal and the Milestones and Timeline as contemplated by this Agreement. Grantee’s obligations pursuant to this Article 13 shall include without limitation any claim by Grantee’s officers, directors, agents, employees, and representatives (including without limitation its Subcontractors, Collaborators, and Service Providers).

“Claim,” as used in this Agreement, means any financial loss, claim, suit, action, damage or expense, including but not limited to attorneys’ fees, attributable for bodily injury, sickness, disease, or death, or injury to or destruction of tangible property including loss of use resulting therefrom. Grantee’s obligations to indemnify, defend, and hold harmless include any claim by Grantee’s agents, employees, representatives, or any subcontractor or its employees.

ARTICLE 14. FAILURE TO ENFORCE

The failure of Grantor at any time, or for any period of time, to enforce any of the provisions of this Agreement shall not be construed as a waiver of such provisions or as a waiver of the right of Grantor thereafter to enforce each and every such provision.

ARTICLE 15. RELATIONSHIP OF THE PARTIES

The relationship of the parties is that of independent contractors. Nothing herein is intended or shall be

construed to establish any agency, partnership, or joint venture. Neither party is authorized or empowered to act as an agent for the other party for any purpose and neither party shall be bound by the acts or conduct of the other party.

ARTICLE 16. GOVERNING LAW

This Agreement shall be governed and construed in accordance with the laws of the state of Washington.

ARTICLE 17. ASSIGNMENT

This Agreement shall not be assigned by Grantee without the advance written consent of Grantor and any attempted assignment shall be null and void. Grantor may assign this Agreement subject to authorization by statutory amendment or its Board of Directors. Upon such assignment, Grantor’s assignee shall accept all rights and assume all obligations herein.

ARTICLE 18. NO ORAL MODIFICATIONS

This Agreement may not be changed, modified, or amended except by express written agreement of the parties executed by their authorized representatives.

ARTICLE 19. NOTICES

Except as otherwise expressly provided in this Agreement, any communications between the parties hereto or notices to be given hereunder shall be given in writing by personal delivery, electronic transmission using electronic mail or Grantor’s online systems, facsimile, or mailing the same, postage prepaid to Grantee or Grantor at the address or number set forth below, or to such other addresses or numbers as either party may indicate pursuant to this section. Any communication or notice so addressed and mailed shall be effective five days after mailing. Any communication or notice delivered by facsimile shall be effective on the day the transmitting machine generates a receipt of the successful transmission, if transmission was during normal business hours of the recipient, or the next business day, if transmission was outside normal business hours of the recipient. Any communication or notice given by personal delivery shall be effective when actually delivered. Communications by Grantee to Grantor using Grantor’s online systems as required under this Agreement shall be effective upon Grantee’s receipt of confirmation that such communications have been received by Grantor.

Communications by electronic mail shall be effective upon the sender’s receipt of confirmation from the recipient that such communications have been received.

Notices to Grantor:

Notices to Grantor shall be submitted to:

Andy Hill CARE Fund

Email: [***]

Address: For notifications that require a physical address, an address will be provided upon request.

All invoices should be submitted electronically to [***].

Additionally, all notices to Grantor shall be copied to:

Laura Flores Cantrell Andy Hill CARE Fund

Email: [***]

Address: For notifications that require a physical address, an address will be provided upon request.

Notices to Grantee: Principal Investigator

Name: Michelle Nelson

Title: Senior Director, Immunobiology Organization: Aptevo Therapeutics Inc.

Address: 2401 4th Ave. Suite 1050, Seattle, WA 98121

Tel: [***]

Email: [***]

Notices to Grantee: Authorized Official

Name: Michelle Nelson

Title: Senior Director, Immunobiology Organization: Aptevo Therapeutics Inc.

Address: 2401 4th Ave. Suite 1050, Seattle, WA 98121

Tel: [***]

Email: [***]

Notices to Grantee: Financial Official

Name: Daphne Taylor Title: SVP & CFO

Organization: Aptevo Therapeutics Inc.

Address: 2401 4th Ave. Suite 1050, Seattle, WA 98121

Tel: [***]

Email: [***]

ARTICLE 20. ENTIRE AGREEMENT

This Agreement and the Attachments attached hereto express the entire understanding of the parties with reference to the subject matter hereof, and supersede any prior or contemporaneous representations, understandings, and agreements, whether oral or written. The parties agree and acknowledge that the rule of construction that ambiguities in a written agreement be construed against its drafter shall not be applicable to this Agreement.

ARTICLE 21. FORCE MAJEURE

Neither Grantor nor Grantee shall be held responsible for delay or default caused by fire, civil unrest, natural causes, and war which is beyond, respectively, Grantor’s or Grantee’s reasonable control. Each party shall, however, make all reasonable efforts to remove or eliminate such cause of delay or default and shall, upon cessation of the cause, diligently pursue performance of its obligations under this

Agreement.

ARTICLE 22. SEVERABILITY

The provisions of this Agreement are intended to be severable. If any term or provision is illegal or invalid for any reason whatsoever, such illegality or invalidity shall not affect the validity of the remainder of the Agreement.

ARTICLE 23. DISPUTES

The parties agree that, in the event of a dispute between them arising from, concerning, or in any way related to this Agreement, they shall undertake good faith efforts to resolve the matter amicably. The parties agree that neither shall initiate an action in court or an administrative tribunal against the other without giving [***] notice of its intent, so that the parties may attempt to resolve the issues without resort to litigation.

ARTICLE 24. NO THIRD-PARTY BENEFICIARIES

Grantor and Grantee are the only parties to this Agreement and, except to the extent that Grantor has delegated to Administrator the authority to act on Grantor’s behalf in enforcing its rights and interests hereunder, Grantor and Grantee are the only parties entitled to enforce its terms. The parties agree that Grantee’s [***] for the benefit of Grantor to enable it to accomplish its fundamental governmental purpose. Nothing in this Agreement is intended to give, or shall give, whether directly or indirectly, any third party standing to sue to enforce this Agreement.

ARTICLE 25. COUNTERPARTS

To facilitate execution, this Agreement may be executed in as many counterparts as may be required. All counterparts shall collectively constitute a single Agreement. This Agreement may be executed through delivery of duly executed signature pages by electronic transmission.

NOW, THEREFORE, agreement to the terms stated above is indicated by signatures affixed below.